Clinical practice in prostate PET imaging.
PET guided treatment
PSMA PET imaging
diagnosis
imaging
positron emission tomography
prostate cancer
radiotherapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
06
2023
accepted:
24
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Positron emission tomography (PET) imaging in prostate cancer has advanced significantly in the past decade with prostate cancer targeted radiopharmaceuticals now playing a growing role in diagnosis, staging, and treatment. This narrative review focuses on the most commonly used PET radiopharmaceuticals in the USA: prostate-specific membrane antigen (PSMA), fluciclovine, and choline. 18F-fluorodeoxyglucose (FDG) is used in many other malignancies, but rarely in prostate cancer. Previous literature is discussed regarding each radiopharmaceutical's utility in the settings of screening/diagnosis, initial staging, biochemical recurrence, advanced disease, and evaluation prior to targeted radiopharmaceutical therapy and radiation therapy. PET imaging has demonstrated utility over traditional imaging in various scenarios; however, there are few head-to-head studies comparing PET radiopharmaceuticals. PSMA radiopharmaceuticals are the newest tracers developed and have unique properties and uses, especially at low prostate-specific antigen (PSA) levels. However, each PET radiopharmaceutical has different properties which can affect image interpretation. Choline and fluciclovine have minimal urinary activity, whereas PSMA agents can have high urinary activity which may affect locoregional disease evaluation. Of the three radiopharmaceuticals, only PSMA is approved for both diagnostic and therapeutic indications with
Identifiants
pubmed: 38028142
doi: 10.1177/17588359231213618
pii: 10.1177_17588359231213618
pmc: PMC10666681
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359231213618Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Eur Radiol. 2022 Nov;32(11):7374-7385
pubmed: 35486169
J Nucl Med. 2018 May;59(5):762-768
pubmed: 28986510
J Nucl Med. 2020 Apr;61(4):540-545
pubmed: 31562222
Cancers (Basel). 2022 Jun 18;14(12):
pubmed: 35740665
Radiat Oncol. 2021 Mar 9;16(1):50
pubmed: 33750437
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
Lancet. 2021 May 22;397(10288):1895-1904
pubmed: 33971152
AJR Am J Roentgenol. 2022 Sep;219(3):386-395
pubmed: 35441529
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476
pubmed: 32617640
Radiology. 2021 May;299(2):248-260
pubmed: 33787338
Eur J Cancer. 2023 May;185:178-215
pubmed: 37003085
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Urol Case Rep. 2023 Jun 09;50:102461
pubmed: 37358989
Urol Oncol. 2015 Mar;33(3):109.e23-31
pubmed: 25655681
J Natl Compr Canc Netw. 2010 Feb;8(2):162-200
pubmed: 20141676
Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39
pubmed: 29037965
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S5-10
pubmed: 23429934
Nat Rev Urol. 2023 Jan;20(1):5-6
pubmed: 36316467
J Nucl Med. 2021 Jun 1;62(6):823-828
pubmed: 33127624
Clin Genitourin Cancer. 2021 Jun;19(3):230-236
pubmed: 32863189
Abdom Radiol (NY). 2020 Dec;45(12):4063-4072
pubmed: 32417934
Urol Oncol. 2021 Jun;39(6):365.e9-365.e16
pubmed: 33160848
Cancers (Basel). 2019 Sep 11;11(9):
pubmed: 31514479
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Eur Urol Oncol. 2022 Oct;5(5):530-536
pubmed: 35697600
Front Oncol. 2021 Jun 17;11:684629
pubmed: 34222008
Radiology. 2021 May;299(2):261-263
pubmed: 33788590
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
Clin Nucl Med. 2013 May;38(5):305-14
pubmed: 23486334
J Urol. 2013 Apr;189(4):1308-13
pubmed: 23123372
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):385-390
pubmed: 31363165
Radiographics. 2019 May-Jun;39(3):822-841
pubmed: 31059396
Radiographics. 2016 Jan-Feb;36(1):279-92
pubmed: 26761541
Eur Urol Oncol. 2021 Oct;4(5):821-825
pubmed: 32088155
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):55-69
pubmed: 26450693
Eur Urol Focus. 2021 Mar;7(2):238-240
pubmed: 33386288
J Nucl Med. 2020 Jun;61(6):827-833
pubmed: 31862801
J Urol. 2020 Oct;204(4):734-740
pubmed: 32347780
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9-15
pubmed: 31654093
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Transl Androl Urol. 2021 Jul;10(7):3117-3129
pubmed: 34430415
J Nucl Med. 2019 Oct;60(10):1350-1358
pubmed: 31481573
Rev Urol. 2004;6 Suppl 10:S13-8
pubmed: 16985927
JAMA Netw Open. 2023 May 1;6(5):e2314748
pubmed: 37219907
J Nucl Med. 2020 Mar;61(3):337-343
pubmed: 31420496
J Nucl Med. 2018 May;59(5):733-739
pubmed: 29523631
J Nucl Med. 2022 Jan;63(1):59-68
pubmed: 34593595
J Nucl Med. 2017 Jan;58(1):81-84
pubmed: 27660139
Radiother Oncol. 2011 May;99(2):193-200
pubmed: 21620494
Radiology. 2019 Nov;293(2):350-358
pubmed: 31502937
Eur Urol. 2013 Jul;64(1):106-17
pubmed: 23628493
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92-101
pubmed: 27557844